LeonaBio, Inc. Market Cap ($44.81 Million)
Market Cap & Net Worth: LeonaBio, Inc. (LONA)
LeonaBio, Inc. market cap. LeonaBio, Inc. (NASDAQ:LONA) has a market capitalization of $44.81 Million ($44.81 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22127 globally and #4931 in its home market, demonstrating a 0.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LeonaBio, Inc.'s stock price $4.77 by its total outstanding shares 9393514 (9.39 Million). Also see LeonaBio, Inc. operating cash flow efficiency for how efficiently the company converts equity into cash flow.
LeonaBio, Inc. Market Cap History (2026–2026)
LeonaBio, Inc. market cap history from 2026 to 2026. Data shows growth from $44.81 Million to $44.81 Million (0.00% CAGR). Check current stock price of LeonaBio, Inc. for real-time trading data and today's change.
LeonaBio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LeonaBio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LeonaBio, Inc. (LONA) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LONA by Market Capitalization
Companies near LeonaBio, Inc. in the global market cap rankings as of November 4, 2026. Also see LeonaBio, Inc. balance sheet assets for a full breakdown of the balance sheet.
Key companies related to LeonaBio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of LeonaBio, Inc. (2026–2026)
Market capitalization of LeonaBio, Inc. from 2026 to today. Between 2026 and today, LeonaBio, Inc.'s market cap moved from $44.81 Million to $ 44.81 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $44.81 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of LeonaBio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.81 Million USD |
| MoneyControl | $44.81 Million USD |
| MarketWatch | $44.81 Million USD |
| marketcap.company | $44.81 Million USD |
| Reuters | $44.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more